Search research articles
Contact Us
Filters
Showing results (51-60 of 66) with videos related to
Page
of 7
Sort By:
Journal of Clinical Pharmacology
|
May 4, 2019
Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy Adults
Jincheng Yang, Mina Nikanjam, Edmund V Capparelli, et al.
The Journal of Antimicrobial Chemotherapy
|
January 19, 2026
Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic -pharmacodynamic modelling in adults and infants
Dustin Huynh, Mina Nikanjam, Coleen K Cunningham, et al.
American Journal of Cancer Research
|
May 10, 2024
Transcriptomic analysis of GITR and GITR ligand reveals cancer immune heterogeneity with implications for GITR targeting
Peter Moussa, Razelle Kurzrock, Daisuke Nishizaki, et al.
The Pediatric Infectious Disease Journal
|
August 18, 2022
Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life
Marlon Liyanage, Mina Nikanjam, Lynn McFadyen, et al.
Immunotargets and Therapy
|
September 12, 2025
B7-H3/CD276: Novel Immune Checkpoint and Jack of All Trades
Brigid Larkin, Daisuke Nishizaki, Hirotaka Miyashita, et al.
Journal of Clinical Pharmacology
|
April 18, 2018
Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach
Jincheng Yang, Maulik Patel, Mina Nikanjam, et al.
Journal of Clinical Pharmacology
|
December 17, 2025
Population Pharmacokinetics of Bictegravir During Pregnancy and Postpartum: Role of Adherence in Maintaining Therapeutic Exposure
Steven Sun, Mina Nikanjam, Mark Mirochnick, et al.
Oncoimmunology
|
March 3, 2020
Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity
Shumei Kato, Ryosuke Okamura, Yuichi Kumaki, et al.
NPJ Precision Oncology
|
July 24, 2025
Gene- and immune-targeted therapy combinations using dual-matched biomarkers for patient selection
Daisuke Nishizaki, Razelle Kurzrock, Jacob J Adashek, et al.
AIDS (London, England)
|
December 7, 2021
Impact of CYP2B6 genotype, tuberculosis therapy, and formulation on efavirenz pharmacokinetics in infants and children under 40 months of age
Mina Nikanjam, Lana Tran, Ellen G Chadwick, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 66) with videos related to
Sort By:
Page
of 7
Journal of Clinical Pharmacology
|
May 4, 2019
Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy Adults
Jincheng Yang, Mina Nikanjam, Edmund V Capparelli, et al.
The Journal of Antimicrobial Chemotherapy
|
January 19, 2026
Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic -pharmacodynamic modelling in adults and infants
Dustin Huynh, Mina Nikanjam, Coleen K Cunningham, et al.
American Journal of Cancer Research
|
May 10, 2024
Transcriptomic analysis of GITR and GITR ligand reveals cancer immune heterogeneity with implications for GITR targeting
Peter Moussa, Razelle Kurzrock, Daisuke Nishizaki, et al.
The Pediatric Infectious Disease Journal
|
August 18, 2022
Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life
Marlon Liyanage, Mina Nikanjam, Lynn McFadyen, et al.
Immunotargets and Therapy
|
September 12, 2025
B7-H3/CD276: Novel Immune Checkpoint and Jack of All Trades
Brigid Larkin, Daisuke Nishizaki, Hirotaka Miyashita, et al.
Journal of Clinical Pharmacology
|
April 18, 2018
Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach
Jincheng Yang, Maulik Patel, Mina Nikanjam, et al.
Journal of Clinical Pharmacology
|
December 17, 2025
Population Pharmacokinetics of Bictegravir During Pregnancy and Postpartum: Role of Adherence in Maintaining Therapeutic Exposure
Steven Sun, Mina Nikanjam, Mark Mirochnick, et al.
Oncoimmunology
|
March 3, 2020
Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity
Shumei Kato, Ryosuke Okamura, Yuichi Kumaki, et al.
NPJ Precision Oncology
|
July 24, 2025
Gene- and immune-targeted therapy combinations using dual-matched biomarkers for patient selection
Daisuke Nishizaki, Razelle Kurzrock, Jacob J Adashek, et al.
AIDS (London, England)
|
December 7, 2021
Impact of CYP2B6 genotype, tuberculosis therapy, and formulation on efavirenz pharmacokinetics in infants and children under 40 months of age
Mina Nikanjam, Lana Tran, Ellen G Chadwick, et al.
Page
of 7